This review concluded that there was some evidence, from three trials, to suggest that both etanercept and infliximab are efficacious treatments for psoriatic arthritis. Short-term benefits for joint and psoriasis symptoms and functional status were observed with both drugs, but further research is needed to assess the long-term benefits. The review was well conducted and its conclusions are likely to be reliable.
Other measures of these outcomes reported by the studies were also included.
How were decisions on the relevance of primary studies made?
Two reviewers independently screened studies for the review. Any discrepancies were resolved by consensus or by referral to a third reviewer.
Assessment of study quality
Study quality was assessed using the following criteria: specification of patient eligibility criteria; a priori sample size calculation; adequate sample size for the analysis of the primary outcome; randomisation method; double-blinding; allocation concealment; blinded treatment providers; blinded outcome assessors; blinded patients; success of the blinding procedure; sufficient patient baseline data reported; comparability of the treatment groups at baseline; comparability of the treatment groups with respect to cointerventions; adequate treatment compliance; all randomised patients accounted for at end of trial; intention-to-treat analysis; at least 80% of the randomised patients provided primary outcome data. The studies were classed as excellent, good, satisfactory or poor quality. One reviewer assessed the studies for quality and a second reviewer checked the assessment. Any disagreements were resolved by consensus or by referral to a third reviewer. The quality of adverse event studies was not assessed.
Data extraction
One reviewer extracted the data and a second checked the extraction. Any disagreements were resolved by consensus or by referral to a third reviewer. Relative risks (RRs) or mean differences, along with the corresponding 95% confidence intervals (CIs), were calculated for the primary outcome variables of joint count (ACR 20, 50 and 70), PsARC, PASI and HAQ.
Methods of synthesis
How were the studies combined? Where pooling was appropriate, pooled RRs or weighted mean differences were obtained using a fixed-effect model.
How were differences between studies investigated?
Differences between the studies regarding adult status, minimum PASI score and concomitant medication were described narratively. Statistical heterogeneity was assessed using a chi-squared test.
Results of the review
Three RCTs, two evaluating etanercept (n=60 and n=205) and one evaluating infliximab (n=104), provided results on efficacy. Twenty-five studies provided data on adverse events (10 for etanercept and 15 for infliximab; number of participants not reported).
Etanercept.
The two etanercept trials were both considered good quality. They satisfied all quality criteria except an assessment of whether blinding had been successful. At 12 weeks, patients treated with etanercept demonstrated statistically significant improvements in arthritis-related symptoms compared with placebo. Etanercept patients were more likely to achieve ACR response criteria relating to 20, 50 or 70% reductions in tender and swollen joint counts: 65% achieved ACR20 (RR 4.19, 95% CI: 2.74, 6.42), 45% achieved ACR50 (RR 10.84, 95% CI: 4.47, 26.28) and 12% achieved ACR70 (RR 16.28, 95% CI: 2.20, 120.54) . Almost 85% of etanercept patients achieved a PsARC (RR 2.60, 95% CI: 1.96, 3.45). Etanercept patients also experienced a statistically significant improvement in functional status. Similar results were observed after 24 weeks of follow-up. There was no evidence of statistical heterogeneity for any outcome.
Infliximab.
The one trial of infliximab was assessed as being of good quality. At 16 weeks, 65% of patients treated with infliximab achieved ACR20 (RR 6.80, 95% CI: 2.89, 16.01), 46% achieved ACR50 (RR 49.00, 95% CI: 3.06, 785.06) and 29% achieved ACR70 (RR 31.00, 95% CI: 1.90, 504.86); infliximab was significantly superior to placebo for all these outcomes. For PsARC, the response rates were 75% for infliximab and 21% for placebo (RR 3.55, 95% CI: 2.05, 6.13). Infliximab patients also experienced a statistically significant improvement in functional status (mean difference of improvement from baseline 51.4%, 95% CI: 48.1, 54.7).
Adverse events. Etanercept appeared to be well-tolerated for short-and long-term use. The most common adverse effects reported were injection site reactions and mild infections. Infusion reactions, antibody development and infections were the most common adverse events for infliximab.
